Akebia Therapeutics, Inc.

AKBANASDAQHealthcare● Active

$0.94

+$0.00(+0.03%)

Market Cap$250982184

P/E Ratio—

52W High$4.079

52W Low$0.875

Avg Volume3.6M

Open$0.95

Beta0.25

Overview

Akebia Therapeutics, Inc. (AKBA) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · AKBA · as of Jun 9, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.04

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 4%Active transactions only · RSU vesting excluded96% Sell ↓

Akebia Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

AKBA insider buying and selling by quarter

AKBA insider selling · AKBA insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

4.5M2.2M0

2023 Q2

2023 Q3

2024 Q1

2024 Q2

2025 Q1

2025 Q2

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Active insiders

Most active in past 12 months · AKBA ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

AKBA executive sell shares · AKBA board member insider trading · AKBA insider trading SEC filing

Showing 59 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Mar 4, 2026	Butler John P. CEO and President · Director	Purchase	69,270	$1.25	$87K	3,367,064	Form 4
Feb 2, 2026	Malabre Richard C SVP, Chief Accounting Officer	Sale	36,142	$1.39	$50K	312,772	Form 4
Feb 2, 2026	Malabre Richard C SVP, Chief Accounting Officer	Sale	13,382	$1.39	$19K	299,390	Form 4
Feb 2, 2026	Grund Nicholas Chief Commercial Officer	Sale	53,585	$1.39	$74K	592,994	Form 4
Feb 2, 2026	Grund Nicholas Chief Commercial Officer	Sale	31,244	$1.39	$43K	561,750	Form 4
Feb 2, 2026	Burke Steven Keith SVP, Chief Medical Officer	Sale	21,582	$1.39	$30K	994,508	Form 4
Feb 2, 2026	Burke Steven Keith SVP, Chief Medical Officer	Sale	25,375	$1.39	$35K	969,133	Form 4
Feb 2, 2026	Burke Steven Keith SVP, Chief Medical Officer	Sale	20,701	$1.39	$29K	948,432	Form 4
Feb 2, 2026	Rucci Carolyn M. SVP, Chief Legal Officer	Sale	16,846	$1.39	$23K	641,304	Form 4
Feb 2, 2026	Rucci Carolyn M. SVP, Chief Legal Officer	Sale	25,382	$1.39	$35K	615,922	Form 4
Feb 2, 2026	Rucci Carolyn M. SVP, Chief Legal Officer	Sale	27,544	$1.39	$38K	588,378	Form 4
Feb 2, 2026	Ostrowski Erik SVP, CFO, CBO & Treasurer	Sale	34,951	$1.39	$49K	672,635	Form 4
Feb 2, 2026	Butler John P. CEO and President · Director	Sale	46,660	$1.39	$65K	3,417,189	Form 4
Feb 2, 2026	Butler John P. CEO and President · Director	Award	175,250	$1.41	$247K	3,381,483	Form 4
Feb 2, 2026	Butler John P. CEO and President · Director	Sale	96,065	$1.39	$134K	3,321,124	Form 4
Feb 2, 2026	Butler John P. CEO and President · Director	Sale	83,689	$1.39	$116K	3,297,794	Form 4
Feb 2, 2026	Butler John P. CEO and President · Director	Sale	114,891	$1.39	$160K	3,206,233	Form 4
Jan 30, 2026	Grund Nicholas Chief Commercial Officer	Award	204,000	—	—	646,579	Form 4
Jan 30, 2026	Burke Steven Keith SVP, Chief Medical Officer	Award	204,000	—	—	1,016,090	Form 4
Jan 30, 2026	Rucci Carolyn M. SVP, Chief Legal Officer	Award	190,000	—	—	658,150	Form 4
Jan 30, 2026	Malabre Richard C SVP, Chief Accounting Officer	Award	79,000	—	—	348,914	Form 4
Jan 30, 2026	Ostrowski Erik SVP, CFO, CBO & Treasurer	Award	204,000	—	—	707,586	Form 4
Jan 30, 2026	Butler John P. CEO and President · Director	Award	743,000	—	—	3,463,849	Form 4
Jun 30, 2025	Ostrowski Erik SVP, CFO, CBO & Treasurer	Sale	41,314	$3.67	$152K	503,586	Form 4
Jun 10, 2025	ZUMWALT LEANNE M Director	Award	35,700	—	—	109,400	Form 4

Butler John P.

CEO and President · Director

Purchase

Date

Mar 4

69,270

Price

$1.25

Value

$87K

View Form 4 on SEC.gov

Malabre Richard C

SVP, Chief Accounting Officer

Sale

Date

Feb 2

36,142

Price

$1.39

Value

$50K

View Form 4 on SEC.gov

Malabre Richard C

SVP, Chief Accounting Officer

Sale

Date

Feb 2

13,382

Price

$1.39

Value

$19K

View Form 4 on SEC.gov

Grund Nicholas

Chief Commercial Officer

Sale

Date

Feb 2

53,585

Price

$1.39

Value

$74K

View Form 4 on SEC.gov

Grund Nicholas

Chief Commercial Officer

Sale

Date

Feb 2

31,244

Price

$1.39

Value

$43K

View Form 4 on SEC.gov

Burke Steven Keith

SVP, Chief Medical Officer

Sale

Date

Feb 2

21,582

Price

$1.39

Value

$30K

View Form 4 on SEC.gov

Burke Steven Keith

SVP, Chief Medical Officer

Sale

Date

Feb 2

25,375

Price

$1.39

Value

$35K

View Form 4 on SEC.gov

Burke Steven Keith

SVP, Chief Medical Officer

Sale

Date

Feb 2

20,701

Price

$1.39

Value

$29K

View Form 4 on SEC.gov

Rucci Carolyn M.

SVP, Chief Legal Officer

Sale

Date

Feb 2

16,846

Price

$1.39

Value

$23K

View Form 4 on SEC.gov

Rucci Carolyn M.

SVP, Chief Legal Officer

Sale

Date

Feb 2

25,382

Price

$1.39

Value

$35K

View Form 4 on SEC.gov

Rucci Carolyn M.

SVP, Chief Legal Officer

Sale

Date

Feb 2

27,544

Price

$1.39

Value

$38K

View Form 4 on SEC.gov

Ostrowski Erik

SVP, CFO, CBO & Treasurer

Sale

Date

Feb 2

34,951

Price

$1.39

Value

$49K

View Form 4 on SEC.gov

Butler John P.

CEO and President · Director

Sale

Date

Feb 2

46,660

Price

$1.39

Value

$65K

View Form 4 on SEC.gov

Butler John P.

CEO and President · Director

Award

Date

Feb 2

175,250

Price

$1.41

Value

$247K

View Form 4 on SEC.gov

Butler John P.

CEO and President · Director

Sale

Date

Feb 2

96,065

Price

$1.39

Value

$134K

View Form 4 on SEC.gov

Butler John P.

CEO and President · Director

Sale

Date

Feb 2

83,689

Price

$1.39

Value

$116K

View Form 4 on SEC.gov

Butler John P.

CEO and President · Director

Sale

Date

Feb 2

114,891

Price

$1.39

Value

$160K

View Form 4 on SEC.gov

Grund Nicholas

Chief Commercial Officer

Award

Date

Jan 30

204,000

Price

—

Value

—

View Form 4 on SEC.gov

Burke Steven Keith

SVP, Chief Medical Officer

Award

Date

Jan 30

204,000

Price

—

Value

—

View Form 4 on SEC.gov

Rucci Carolyn M.

SVP, Chief Legal Officer

Award

Date

Jan 30

190,000

Price

—

Value

—

View Form 4 on SEC.gov

Malabre Richard C

SVP, Chief Accounting Officer

Award

Date

Jan 30

79,000

Price

—

Value

—

View Form 4 on SEC.gov

Ostrowski Erik

SVP, CFO, CBO & Treasurer

Award

Date

Jan 30

204,000

Price

—

Value

—

View Form 4 on SEC.gov

Butler John P.

CEO and President · Director

Award

Date

Jan 30

743,000

Price

—

Value

—

View Form 4 on SEC.gov

Ostrowski Erik

SVP, CFO, CBO & Treasurer

Sale

Date

Jun 30

41,314

Price

$3.67

Value

$152K

View Form 4 on SEC.gov

ZUMWALT LEANNE M

Director

Award

Date

Jun 10

35,700

Price

—

Value

—

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About AKBA insider trading

AKBA insider trades

Akebia Therapeutics, Inc. (AKBA) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Butler John P. (CEO and President · Director), Burke Steven Keith (SVP, Chief Medical Officer), Rucci Carolyn M. (SVP, Chief Legal Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. AKBA insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Akebia Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

AKBA insider trading · 5 questions

The insiders of Akebia Therapeutics, Inc. (AKBA) include executives and directors such as Butler John P. (CEO and President · Director), Burke Steven Keith (SVP, Chief Medical Officer), Rucci Carolyn M. (SVP, Chief Legal Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

AKBA board member insider tradingwho are AKBA insidersAKBA insider rosterAkebia Therapeutics, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026